Product Description
Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation. (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa2002787)
Mechanisms of Action: C-Met Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Malaysia | Norway | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United States
Approved Indications: Non-Small-Cell Lung Cancer | Oncology Unspecified
Known Adverse Events: Dyspnea | Edema
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Belgium, Brazil, Canada, China, Colombia, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Japan, Korea, Lebanon, Lithuania, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, Singapore, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 19
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 2: Adenocarcinoma|Gastrointestinal Cancer|Hepatocellular Carcinoma|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-205439 | P2 |
Active |
Non-Small-Cell Lung Cancer |
2032-02-25 |
|
| 2016-005144-42 | P2 |
Active, not recruiting |
Other |
2027-12-19 |
|
| CINC280A2X02B | P2 |
Unknown Status |
Other |
2027-07-30 |
|
| CINC280A2X02B | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2027-07-30 |